Abstract Library

#3019 Incomplete Peptide Receptor Radionuclide Therapy Courses - Are We Selecting Our Patients Appropriately?

Introduction: As per recommendations, a Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 DOTATATE course usually consists of 4 cycles. Patients may discontinue a PRRT course early, either due to progression or toxicity. Limited data are available about predictive factors for PRRT early discontinuation.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Julian G

Authors: Gertner J, Groves J, Aziz B, Miah L, Furtado O'Mahony L,

Keywords: prrt,

#2841 Novelties in Primary and Metastatic GEP-NENs Clinical Outcome Investigation

Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) WHO classification, using strict cut-offs, should reflect their biological features. In real world, strict cut-offs not adequately segregate prognostic groups, in particular on metastasis (M).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Milione M

Authors: Kankava K, Maisonneuve P, Mangogna A, Centonze G, Cattaneo L,

Keywords: Gastro-entero-pancreatic neuroendocrine neoplasms, primary tumor, metastasis, Ki-67, mitoses, tumor deposits, clinical outcomes,

#2784 Predictive Factors of Tumor Recurrence after Radical Surgery for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs): Identification of High-Risk Subgroups

Introduction: There is no proven role for adjuvant medical therapy after curative surgery (R0) for GEP-NENs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rossi R

Authors: Rossi R, Altomare M, Monteleone M, Prinzi N, Pusceddu S,

Keywords: radical surgery, recurrence, gastro-entero-pancreatic neuroendocrine neoplasms, prognostic factors,

#2736 Second Primary Neoplasms in Patients with Neuroendocrine Neoplasms (NEN): DATA from a Retrospective Multicentric Study

Introduction: Patients with sporadic gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) may exhibit a higher risk of second primary tumors than the general population.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Massironi S

Authors: Massironi S, Campana D, Pusceddu S, Albertelli M, Faggiano A,

Keywords: GEP-NEN, Second primary neoplasm (PMN), Overall survival (OS),

#2248 High Grade (G3) Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Should the New WHO Classification Apply to All?

Introduction: Grade 3 (G3) neuroendocrine neoplasms (NEN), arising from the gastro-entero-pancreatic system (GEP), are classified according to WHO 2010 and defined as having a Ki67 of > 20%. However this groups together G3 well differentiated neuroendocrine tumours (WD-NET) with poorly differentiated neuroendocrine carcinomas (PD-NEC). Recently, WHO have proposed a new classification for pancreatic NEN, with sub-division into G3 WD-NET and G3 PD-NEC

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Furnace M

Authors: Furnace M, Muller G, Rundell C, Shah R, Luong T,

Keywords: G3, well-differentiated, poorly differentiated, Ki-67,